TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Remission from a major depressive episode after ECT treatment~Exclusion Criteria:~* Suicidality (Hamilton item 3 score of 3 or more)~* Symptoms mania (MAS score of 15 or more)~* Duration of actual depressive episode more than 2 years~* Compulsory measures of any kind~* Dementia~* Severe somatic illness~* Pregnant or lactating subject~* Known clinical relevant malabsorption.~* Epilepsia~* Clinically substantial cognitive deterioration due to ECT treatment~* schizophrenia, schizopreniform or schizo-affective disorder~* Bipolar I, Bipolar II eller~* Rapid cycling bipolar disorder~* Abuse of alcohol or drugs~* Early relapse (less than 2 month) after ECT~* Inadequate contraception~* Known intolerance to any of the used study medications~* Myocardial infarction in the last 6 month~* Clinical important liver disease~* Any known disturbance of the cardiac conduction system, cardiac insufficiency,or other clinical important cardiac disease~* Treatment with a MAO-inhibitor~* Treatment with norepinephrine or epinephrine~* Known hyperthyroidism or treatment with thyroid hormones~* Known ortostatic hypertension.~* Glaucoma~* Known hereditary galactoseintolerance, Lapp Lactase deficiency) or gluco-se/galactosemalabsorption.~* Ongoing treatment with sympatomimetica efedrine, isoprenaline, physostigmine, dopamine, levodopa, phenylephrine.~* Ongoing treatment with anticholinergica, antiparkinson treatment, antihistamines, atropine, biperiden,~* Ongoing treatment with drugs that prolongs the cardiac QT-interval, such as quinidine, antihistamines, terfenadine og sotalole~* Ongoing treatment with fluconazole or terbinafine~* Ongoing treatment with mefloquin.~* Known intolerance to escitalopram~* Ongoing treatment with serotonergic acting substances such as tramadole, sumatriptane

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Escitalopram 10 mg daily (Type: EXPERIMENTAL): Escitalopram 10 mg daily
- Escitalopram 20 mg daily (Type: EXPERIMENTAL): Escitalopram 20 mg daily
- escitalopram 30 mg daily (Type: EXPERIMENTAL): escitalopram 30 mg daily
- Nortriptylin 100 mg daily (Type: ACTIVE_COMPARATOR): Nortriptylin 100 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Techniques to Reduce the Severity and Frequency of Emergent Reactions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 18 years of age~* Required need for procedural sedation and analgesia~Exclusion Criteria:~* Age\< 18~* Hypertension~* Raised Intracranial pressure~* Major psychological disorders~* Procedures involving laryngel manipulations~* History of Laryngeal sapsm History of adverse reactions to ketamine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Packet 1: The Physician will be asked to instruct the patient as empathetically and confidently as possible, that the drug the patient will be given will make them feel no pain, cause them to forget the procedure, and allow them to dream the dream of their choice.
- Control Arm (Type: OTHER): Half of the participants will receive the sedation medication with the usual conversation while the physician is giving the medication to the patient. The other half of the participants will have a more positive conversation, (which is the study intervention), with the physician while being given the medication. Both group's emergence reactions, if any, will be compared to see if the positive conversation reduced the side effect.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Resveratrol Trial for Relief of Pain in Pseudoachondroplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The diagnosis of pseudoachondroplasia is based on clinical assessment either in person or by photographic review by skeletal dysplasia specialist (JTH),~* Healthy beyond pseudoachondroplasia associated complications,~Exclusion Criteria:~* Current use of resveratrol~* Current use of blood thinners, lovastatin, ketoconazole, itraconazole, fexofenadine and triazolam.~* Other non-pseudoachondroplasia related health conditions, e.g. cancers.~* Pregnancy or breastfeeding. Women must use adequate contraception during the study.~* Participation in another clinical study and/or using investigational agents.~* Use of Non-steroid anti-inflammatory (NSAIDs) or aspirin.~* Current use of Alfentanil, Cyclosporine, Dihydroergotamine, Dofetilide, Ergotamine, Fentanyl, Flibanserin, Oxycodone, Pimavanserin, Pimozide, Quinidine, Saquinavir, Sirolimus, Tacrolimus, Temsirolimus, Theophylline, Tizanidine, Thioridazine, Fosphenytoin, Phenytoin or Warfarin.~* Baseline level of pain of 2 or higher on 10 point scale.~* Platelet count below 50,000 per ul on baseline complete blood count (CBC).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Resveratrol, Then Placebo (Type: EXPERIMENTAL): Participants first received Resveratrol 125 mg/day or 5 ml daily for 90 days. After a washout period of 30 days, they then received Placebo 5ml daily for 90 days.
- Placebo, Then Resveratrol (Type: PLACEBO_COMPARATOR): Participants first received Placebo 5ml daily for 90 days. After a washout period of 30 days, they then received Resveratrol 125 mg/day or 5 ml daily for 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of advanced NSCLC not amenable to curative treatment. Participants enrolling in Part 2 of the study must have the above stated diagnosis of NSCLC that is also of nonsquamous histology.~* no prior systemic therapies \[chemotherapy, et cetera (etc.)\] or pleurodesis with chemotherapy for this disease~* prior radiotherapy is allowed but must be completed at least 2 weeks before study enrollment and participant must be recovered from the acute toxic effects~* have a good performance status~* participant must sign an informed consent document~Exclusion Criteria:~* participant had myocardial infarction occurring less than 6 months before inclusion, uncontrolled arrhythmia, symptomatic angina pectoris, or cardiac failure not controlled by medications~* participant is unable to swallow tablets~* participant is taking a certain medicine to control seizure activity, called enzyme inducing antiepileptic drugs and is not able to stop taking the medicine prior to enrolling in the study~* participant is unable to interrupt aspirin and/or other anti-inflammatory agents~* participant is unwilling or unable to take vitamin supplementation (folic acid and vitamin B12) or medications to prevent side effects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzastaurin + Pemetrexed + Cisplatin (Type: EXPERIMENTAL): None
- Placebo + Pemetrexed + Cisplatin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Analgesia by ESP Catheter on Paediatric Recipient for Liver Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recipient liver transplantation who accepted to participate ( parents or guardians)~Exclusion Criteria:~* Refusal participation.~* Allergy to LA~* Intubated ventilated pre-operation~* Severe coagulation disorder~* Coma~* Prediction of large volume liver implanted~* After surgery performed Large volume implanted with a need of post operative controlled ventilation~* After surgery performed Organ failure~* After surgery performed Unstable patient

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Standard of cares (Type: NO_INTERVENTION): Peri operative analgesia by opioids
- regional analgesia (Type: EXPERIMENTAL): Peri operative analgesia by continuous bilateral ESP catheters

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of probable Alzheimer Disease (AD), with Mini Mental State Examination (MMSE) score of 16-26, and brain magnetic resonance imaging (MRI) consistent with the diagnosis of AD~* Concurrent use of cholinesterase inhibitor or memantine allowed, if stable~* Caregiver will participate and be able to attend clinic visits with patient~Exclusion Criteria:~* Significant neurological disease other than AD~* Major psychiatric disorder~* Contraindication to undergo brain MRI \[e.g., pacemaker, cerebrospinal fluid (CSF) shunt, or foreign metal objects in the body\]~* Women of childbearing potential

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Bapineuzumab 0.5 mg/kg (Type: EXPERIMENTAL): None
- Bapineuzumab 1.0 mg/kg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of amyotrophic lateral sclerosis~* clinical indication to start noninvasive ventilation (forced vital capacity \< 50% predicted or signs/symptoms of respiratory insufficiency)~* age 18 to 80 years old~Exclusion Criteria:~* prior institution of NIPPV~* inability to safely use NIPPV~* indications for tracheostomy assisted ventilation because of inability to clear secretions from the airway~* inability or unwillingness to perform pulmonary function testing~* presence of advanced dementia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- High-level ventilation (Type: ACTIVE_COMPARATOR): Each subject will spend 2 hours receiving high-level noninvasive ventilation.
- Low-level ventilation (Type: ACTIVE_COMPARATOR): Each subject will receive 2 hours of low-level noninvasive positive pressure ventilation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Spinal Anesthesia in Patients With Poorly-palpable Surface Landmarks

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting for elective total hip or knee replacement under spinal anesthesia who have poorly palpable or impalpable spinous processes~* BMI ≥ 35 kgm-2~Exclusion Criteria:~* Inability or refusal to provide informed consent,~* Bleeding diathesis,~* Allergy to local anesthetics~* Contra-indication to spinal anesthesia

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Landmark Technique (Type: None): Control group
- Ultrasound guided technique (Type: None): Neuroaxial block using Ultrasound guidance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Biopsy-proven invasive adenocarcinoma of the breast 1.5cm or larger by clinical exam or imaging including ultrasound, mammogram, CT, or MRI~2. Females at least 18 years-old,~3. Not pregnant, as demonstrated by a negative serum or urine pregnancy test in women of child bearing potential, and not planning on becoming pregnant~4. Willing to have a biopsy at the start of study if adequate sample for gene array is not available.~5. Willing to have a biopsy at the end of the trial if breast surgery is not planned.~6. ECOG Performance status 0-2~7. Able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines~Exclusion Criteria:~1. Need for immediate chemotherapy as determined by the patients' physicians, e.g., present or imminent compromise of vital organs or unacceptable symptoms from the tumor.~2. Known hypersensitivity to valproic acid or its components or peanut allergy~3. Inadequate bone marrow, kidney, and liver function (greater than grade 1 by CTCAE version 4) as defined by the protocol.~4. Immunocompromised due to medications or HIV as documented in medical history~5. Use of other antiepileptics or medications with known interactions with valproic acid (See protocol for full list)~6. Inborn errors of metabolism (valproic acid is contraindicated in patients with known urea cycle disorders)~7. History of pancreatitis~8. Use of a ketogenic diet~9. Inability to have an MRI due to extreme claustrophobia, possible metal fragments in the eye, cardiac pacemaker, implanted cardiac defibrillator, aneurysm clips, carotid artery vascular clamp, neurostimulator, insulin or infusion pump, implanted drug infusion device, bone growth/fusion stimulator, or cochlear, otologic, or ear implant~10. Tumor that is unlikely to yield adequate tissue for genomic studies in the opinion of the principle investigator

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): All participants enrolled.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients scheduled for CABG (males or non-pregnant females)~2. \> 18 years old with at least one vein graft planned~3. Able to provide written informed consent~Exclusion Criteria:~1. Patients who, in the investigator's or attending surgeon's opinion, are unsuitable for anticoagulation due to their clinical status~2. Documented history of allergy to iodinated contrast media, warfarin, or argatroban~3. Chronic renal impairment with CrCl\<60 ml/min~4. Recent bleeding episode~5. Congestive Heart Failure (EF\< 30%)~6. Bleeding diathesis or known thrombophilic disorder~7. Atrial fibrillation or other condition requiring anticoagulation at the time of enrollment~8. Documented history of heparin induced thrombocytopenia~9. Clinical suspicion of HIT at the time of randomization, defined as 50% decrease in Platelet count from last heparin exposure or Platelet count \<100,000/ml~10. Hepatic dysfunction (defined as LFTs \> 3 times the upper limit of normal)~11. Patients with a history of bleeding complications post-CABG~12. Hemorrhagic stroke~13. Gastrointestinal bleeding~14. Requirement for fresh frozen plasma~15. Recent central nervous system or ophthalmic surgery~16. Aneurysm~17. History of psychosis or senility~18. Malignant hypertension~19. Clinically significant pericarditis or pericardial effusion~20. Bacterial endocarditis~21. Hematocrit \< 24%~22. Valve replacement or repair at time of CABG~23. Subjects with signs or symptoms of possible Transient Ischemic Attack or stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Heparin PF4 antibody positive -Drug (argatroban and warfarin) (Type: EXPERIMENTAL): Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin
- Heparin PF4 antibody positive no drug (Type: NO_INTERVENTION): Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication
- Heparin PF4 antibody negative (Type: NO_INTERVENTION): Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of IMNM (Immune-Mediated Necrotizing Myopathy)~* Positive serology for anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) or anti-signal recognition particle (SRP) autoantibodies~* Clinical evidence of weakness (≤ grade 4 out of 5) on manual muscle testing in at least one proximal limb muscle group~* Creatine kinase (CK) of \>1000 U/L at Screening~* No change in corticosteroid dose for at least 30 days prior to Baseline or anticipated to occur during the first 8-weeks on study~* No changes in immunosuppressive therapy, including dose, for at least 30 days prior to Baseline or anticipated to occur during the first 8-weeks on study~Exclusion Criteria:~* History of meningococcal disease~* Current or recent systemic infection within 2 weeks prior to Screening or infection requiring intravenous (IV) antibiotics within 4 weeks prior to Screening~* Recent initiation of intravenous immunoglobulin (IVIG) (i.e., first cycle administered less than 90 days prior to Baseline)~* Rituximab use within 90 days prior to Baseline or anticipated to occur during study~* Statin use within 30 days prior to Baseline or anticipated to occur during study~* Plasma exchange within 4 weeks prior to Baseline or expected to occur during the 8-week Treatment Period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 0.3 mg/kg zilucoplan (Type: EXPERIMENTAL): Daily subcutaneous (SC) injection
- Placebo (Type: PLACEBO_COMPARATOR): Daily subcutaneous (SC) injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy